Top Markets
Coin of the day
Thalia Therapeutics Plc Thalia Therapeutics Plc

Thalia Therapeutics Plc

THAT
Hisse Senetlerindeki Sıralama #40823
Thalia Therapeutics Plc, a specialized pharmaceutical company established in... Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Hisse Fiyatı
$0.00918474
Piyasa Değeri
$76.44K
Değişim (1 gün)
0.00%
Değişim (1 yıl)
38.04%
Ülke
GB
Ticaret Thalia Therapeutics Plc (THAT)

Kategori

Thalia Therapeutics Plc (THAT) için gelir
Aug 2026 itibarıyla gelir TTM: 0
Thalia Therapeutics Plc şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) 0'dir. 2026 yılında şirketin geliri 0 önceki yıla eşit 2026 yılındaki 0 gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Thalia Therapeutics Plc için 2026 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE